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Abstract
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Here, we report the identification and characterization of a novel tyrosine phosphorylation site in
the carboxy-terminal Src Homology 3 (SH3) (SH3C) domain of the Crk adaptor protein. Y251 is
located in the highly conserved RT loop structure of the SH3C, a region of Crk involved in the
allosteric regulation of the Abl kinase. Exploiting kinase assays to show that Y251 is
phosphorylated by Abl in vitro, we generated affinity-purified antisera against phosphorylated
Y251 in Crk and showed that Abl induces phosphorylation at Y251 in vivo, and that the kinetics of
phosphorylation at Y251 and the negative regulatory Y221 site in vitro are similar. Y251 on
endogenous Crk was robustly phosphorylated in chronic myelogenous leukemia cell lines and in
A431 and MDA-MB-468 cells stimulated with epidermal growth factor. Using streptavidin–biotin
pull downs and unbiased high-throughput Src Homology 2 (SH2) profiling approaches, we found
that a pY251 phosphopeptide binds specifically to a subset of SH2 domains, including Abl and
Arg SH2, and that binding of pY251 to Abl SH2 induces transactivation of Abl 1b. Finally, the
Y251F Crk mutant significantly abrogates Abl transactivation in vitro and in vivo. These studies
point to a yet unrealized positive regulatory role resulting from tyrosine phosphorylation of Crk,
and identify a novel mechanism by which an adaptor protein activates a non-receptor tyrosine
kinase by SH2 domain displacement.
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The Crk family of adaptor proteins (Crk II, Crk I and CrkL) comprises cytoplasmic Src
Homology 2 (SH2) and Src Homology 3 (SH3) domain-containing proteins that assemble
protein complexes and transmit signals downstream of tyrosine kinases (Mayer et al., 1988;
Matsuda et al., 1990). Both Crk II and CrkL are composed of a single SH2 domain,
followed by two tandem SH3 domains: SH3(N) and SH3(C) (Matsuda et al., 1992;
Reichman et al., 1992). Crk II is also alternatively spliced to a minor product, Crk I, which
is structurally and functionally more similar to the v-Crk oncogene encoded by the avian
CT10 retrovirus (Feller, 2001; Birge et al., 2009). Despite the fact that both Crk II and CrkL
are ubiquitously expressed, their SH domains are highly homologous, they bind similar
proteins, both are required for mouse development and exhibit distinct non-overlapping
phenotypes in knockout mice (Guris et al., 2001; Park et al., 2006). Identification of
isoform-specific signaling pathways for Crk versus CrkL remains elusive.
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The adaptor function of Crk is mediated by the assemblage of selective signaling protein
complexes that bind to the SH2 and SH3(N) domains in the context of sequence-specific
consensus motifs. The Crk SH2 domain binds to selective targets in the context of a pTyr-XX Pro (Birge et al., 1993), whereas the SH3N domain binds to selective PPII peptides in the
context of Pro-X-X-Pro-X- (Lys, Arg) (Knudsen et al., 1994). Two of the best understood
signaling pathways mediated by Crk arise from ternary complexes of p130cas–Crk–Dock180
(Kiyokawa et al., 1998), which is involved in the activation of Rac1 and actin cytoskeletal
reorganization (Klemke et al., 1998), and p130cas–Crk–C3G (Matsuda et al., 1994), which is
involved in inside-to-outside integrin activation and cell adhesion (Tanaka et al., 1994;
Gotoh et al., 1995).
On the other hand, Crk SH3C is an atypical SH3 domain that does not bind to conventional
PPII motifs (Reichman et al., 2005; Muralidharan et al., 2006). It has been shown to exert a
negative regulatory effect on the binding of ligands to the SH3N (Kobashigawa et al., 2007;
Sarkar et al., 2007). Recently, we have described the structural basis for SH3C
autoinhibition by virtue of the fact that Crk toggles between two conformations—a cisinhibitory conformation stabilized by an intramolecular association of the two SH3 domains
and a trans-uninhibited conformation that unhinges the closed conformation. These
conformations are regulated by cis trans-isomerization at Pro238 (Sarkar et al., 2011).
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Negative regulation of Crk-mediated signaling is achieved by phosphorylation at Y221
(resulting in an intramolecular SH2–pY221 interaction) by the Abl, Arg tyrosine kinases that
bind to the Crk SH3N domain (Feller et al., 1994; Ren et al., 1994). Such negative
regulation is also involved in signaling from several receptor tyrosine kinases, including
EGFR (Hashimoto et al., 1998), platelet derived growth factor beta receptor (Sorokin et al.,
1998; Matsumoto et al., 2000), TrkA (Ribon and Saltiel, 1996) and Ephrin B1/Eph
(Nagashima et al., 2002). However, in addition to its role in the disassembly of Crk protein
complexes, association of Crk and Abl also induces transient Abl transactivation (Shishido
et al., 2001; Reichman et al., 2005), which is mediated by the PNAY motif in the RT loop of
the SH3C domain of Crk (Reichman et al., 2005). Interestingly, Abl is activated downstream
of EGFR, Her2/ErbB2 and Src, and constitutively activated in highly invasive breast cancer
cell lines supporting a tumor-promoting role (Srinivasan and Plattner, 2006; Srinivasan et
al., 2008). However, the consequences of Abl activation by Crk remain to be understood and
the precise mechanism of transactivation of Abl by Crk has still not been elucidated.
In this study, we have identified and characterized Y251 in the RT loop of the SH3C of Crk
as a second phosphorylation site for Abl in addition to the previously identified negative
regulatory site, Y221. Y251, when phosphorylated, binds to the Abl SH2 domain to
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transactivate Abl 1b. These results lend insights into the mechanism of Abl activation by
Crk—a novel mechanism of activation of a non-receptor tyrosine kinase by an adaptor
protein. In addition, our data suggest that tyrosine phosphorylation of Crk can both
positively and negatively regulate Abl activity and signaling pathways.

Results
Crk Y251 within the conserved PNAY motif in the SH3C is phosphorylated by Abl
The SH3C domain of Crk is an atypical SH3 domain in that it does not bind to conventional
PPII-containing ligands (Muralidharan et al., 2006). In a previous study to elucidate the
biological function of this region of Crk, we substituted conserved amino acids on the
surface of SH3C, which were predicted to provide a binding surface for target proteins
(Reichman et al., 2005). In doing so, we identified an important region that was required for
the transactivation of mouse c-Abl type IV (homologous to human c-Abl 1b)—the highly
conserved PNAY motif in the RT loop of SH3C (Reichman et al., 2005).
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To determine whether Y251 within the PNAY motif is phosphorylated by Abl, we coincubated purified human Abl with bacterially expressed and purified glutathione-Stransferase (GST), GST-Crk or GST-Crk Y221F proteins in an in vitro kinase assay (Figure
1a). As indicated, substitution of the negative regulatory Y221 only partially reduced total
tyrosine phosphorylation (by ~50%), suggesting the existence of other tyrosine
phosphorylation sites on Crk. Furthermore, in the in vitro kinase assay described above,
immunoprecipitation of Abl and analysis of the bound fraction revealed the presence of
tyrosine-phosphorylated GST-Crk (Figure 1b), suggesting that a form of GST-Crk
phosphorylated at one or more sites other than Y221 remained associated with Abl. To
investigate whether tyrosine phosphorylation of Y221F Crk occurred in cell lines, we cotransfected CrkI or various mutants of Crk with mouse Abl type IV in 293T cells (Figure
1c). Consistent with the in vitro kinase assay in Figure 1a, total tyrosine phosphorylation
(assayed by western blotting with a general anti-phosphotyrosine antibody) on the Crk
Y221F mutant was again reduced by ~50% compared with wild-type Crk. As Y251 on
human Crk (hCrk) was found to be phosphorylated in K562 cells using mass spectrometric
analysis (http://Phosphosite.org, Cell Signaling Technology, Danvers, MA, USA), we coexpressed Y221F/Y251A or Y221F/P249A double mutants with Abl in 293T cells (Q275 on
the surface of Crk SH3C was also mutated to alanine and the mutant was co-expressed with
Abl). As shown in Figure 1d, tyrosine phosphorylation of the Y221F/Y251A double mutant
was reduced over 50% compared with Y221F, suggesting that Y251 is phosphorylated when
Crk is co-expressed with Abl.
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Generation and characterization of phosphospecific antisera to human phospho (Y251)Crk
To better examine tyrosine phosphorylation of Crk at Y251 in vivo, we generated polyclonal
phosphospecific antisera against the human phospho (Y251) motif using phosphopeptides
coupled to carrier proteins as immunogens and subsequently obtained affinity-purified antiphospho (Y251) antibodies against hCrk. Co-expression of wild-type human or chicken Crk
with human c-Abl 1b in 293T cells resulted in robust immunoreactivity of Crk with the antiphospho-(Y251) Crk antibody. A hCrk Y251F mutant or a chicken Crk (cCrk) Y251A
mutant when co-expressed with Abl showed no immunoreactivity (Figure 2a). Furthermore,
immunoreactivity was completely blocked by the specific pY251 phosphopeptide (derived
from the RT loop of hCrk SH3C with the sequence KRVPNApY251DKTALALE) but not by
a nonspecific pY221 phosphopeptide or by the unphosphorylated GST-Crk protein (Figure
2b), thereby confirming the specificity of the anti-phospho (Y251) antibody.
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To investigate whether phosphorylation of hCrk at Y251 prevented or augmented
phosphorylation at the negative regulatory site Y221 or vice versa, we co-expressed hCrk
Y221F and Y251F with Abl 1b in 293T cells, followed by western blotting with antiphospho (Y221) and anti-phospho (Y251) antibodies. We also co-expressed a Y239F Crk
mutant with Abl as Y239, which, located at the boundary of hCrk SH3C, is a potential
phosphorylation site. No mutant showed reduced or augmented phosphorylation at Y221 or
Y251 (Figure 2c). We also incubated purified human Abl 1a (from insect cells) with
bacterially expressed and purified GST-hCrk in the presence of ATP over a time course of 5
s to 10 min to examine kinetics (Figure 2d). Interestingly, both Y221 and Y251 were
phosphorylated at the earliest time point examined (5 s).
Bcr-Abl induces phosphorylation of endogenous Crk at Y251 in CML cell lines, and EGF
induces phosphorylation of endogenous Crk at Y251 in EGFR-expressing A431 and MDAMB-468 cells
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To investigate whether phosphorylation at Y251 could be detected in CML cell lines in
which Crk is expressed endogenously, we analyzed five different cell lines, four of which
(K562, KCL22, LAMA84 and MEG01) were derived from CML patients in blast crisis
(Figure 3a). In all lines, phosphorylation of hCrk at Y251 was detectable in addition to
phosphorylation at Y221 by western blotting with the anti-phospho (Y251) and the antiphospho (Y221) antibodies, whereas no phosphorylation was detectable in unstimulated
293T cells. To test whether phospho (Y251) was labile to Bcr-Abl inhibition by Imatinib
(Novartis, Boston, MA, USA), either K562 cells or 32D cells expressing wild type (WT)
Bcr-Abl (imatinib-sensitive) or T315I Bcr-Abl (imatinib-insensitive) were treated with 5 μM
imatinib for 2 h. As shown in Figure 3b, imatinib treatment resulted in reduced
phosphorylation at Y251 inWT Bcr-Abl-expressing 32D cells but not in 32D cells
expressing T315I Bcr-Abl, thus suggesting that Bcr-Abl induces phosphorylation of Crk at
Y251 in CML cell lines. We also examined phosphorylation of Crk upon EGF stimulation in
MDA-MB-468 (a human breast cancer cell line) and in A431 (a human vulvo-epithelial
carcinoma cell line) cells. Cells were serum starved and stimulated with EGF for 1, 5 and 30
min. There was basal phosphorylation of Crk at Y251, which was enhanced upon EGF
treatment at the earliest time point examined (1 min, Figure 3c, Supplementary Figure S1).
We also observed phosphorylation of Crk at Y221 upon EGF stimulation. Interestingly, and
in contrast to Bcr-Abl-expressing cells, pretreatment with Imatinib did not abrogate EGFinduced phosphorylation at Y251 suggesting that, in MDA-MB-468 and A431 cells, kinases
other than Abl may impinge on phosphorylation of Crk at Y251 after EGF stimulation
(Figure 3d). To test this further, we co-expressed WT Crk or the W170K mutant (that
renders the Crk SH3N defective in binding to PPII motifs) with Abl or EGFR in 293T cells.
As shown in Figure 3e, the W170K mutant exhibits greatly reduced phosphorylation at
Y251 and Y221 when co-expressed with Abl (left panel) but not when co-expressed with
EGFR and stimulated with EGF (right panel), suggesting that kinases other than Abl,
downstream of EGF stimulation, can impinge on phosphorylation of Crk at Y251 by an
SH3N-independent mechanism.
Phospho (Y251)-derived peptides from hCrk bind directly to the SH2 domain of Abl
To explore the biological function of phospho (Y251), we screened an SH2 domain library
with a chemically synthesized N-terminally biotinylated 16-mer phosphopeptide with a
centrally located phosphotyrosine residue (Biotin-LC-KRVPNApY251DKTALALE, which
will be referred to as pY251) complementary to the phospho (Y251) site in the RT loop.
pY251 was diluted in a rosette-loading buffer and spotted onto gelatin-coated nitrocellulose
membranes (Figure 4a) in register with the wells of a 96-well plate after which each well
was incubated with a different GST-SH2 domain probe (labeled with GSH-horse radish
peroxidase). The summary of the quantified data from replicate experiments showed that
Oncogene. Author manuscript; available in PMC 2012 March 23.
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SH2 domain binding was relatively modest and selective from the 96 SH2 domains tested in
the assay (Figure 4b) with specificity towards Arg, ShcB, Brdg, Abl and SHIP2. We further
examined binding of pY251 to the Abl SH2 domain in a streptavidin–biotin pull-down
assay. Biotinylated pY251 or the unphosphorylated peptide Y251 was incubated with GSTAbl SH2 and pY221 with GST-Crk SH2 (as a positive control for the assay) subsequent to
which streptavidin–agarose beads were added to achieve a pull down. The fraction bound to
beads in each case was analyzed by western blotting with an anti-GST antibody. GST-Abl
SH2 bound to pY251 and not to the unphosphorylated peptide Y251 or to beads (pY251 did
not bind to GST, lane 6). Furthermore, the Abl SH2–pY251 interaction seemed to be weaker
than the Crk SH2–pY221 interaction (Figure 4c, compare lanes 3 and 9). Finally, we
examined the Abl SH2–pY251 interaction by isothermal titration calorimetry
(Supplementary Figure S2). Consistent with the above results, a weak interaction between
the phosphopeptide pY251 and Abl SH2 was detectable by isothermal titration calorimetry
(Kd = 85.5 μM).
Phospho (Y251) is directly involved in the transactivation of Abl 1b
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We next examined the contribution of phosphorylated Y251 of human Crk on
transactivation of Abl by co-expressing wild-type or Y251F hCrk with Abl 1b in 293T cells.
We also co-expressed Y221F (which has been previously shown to transactivate Abl
(Shishido et al., 2001)), Y239F, Y221F/Y239F and Y221F/Y251F hCrk mutants with Abl
1b. Abl activation was examined by western blotting with an anti-phospho (Y245) Abl
antibody. Y251F and Y221F/Y251F mutants transactivated Abl to a lesser extent than did
wild-type hCrk and the Y221F mutant, respectively (Figure 5a). Importantly, in five
independent experiments, Y251F hCrk significantly abrogated Abl transactivation (Figure
5b). We next examined transactivation of Abl 1b by preincubating immunoprecipitated Abl
with purified GST, GST-hCrk or GST-hCrk Y251F, followed by an in vitro kinase assay
and western blotting with an anti-phospho (Y245) antibody (Figure 5c). The Y251F mutant
showed a significantly diminished ability to transactivate Abl compared with wild-type Crk
(the addition of which was sufficient to significantly activate Abl). Furthermore, GST-hCrk
failed to transactivate the Abl SH2 domain mutant, R171L (Supplementary Figure S3),
suggesting that phospho (Y251) on Crk was directly involved in Abl transactivation by SH2
domain displacement.
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Finally, to examine transactivation of Abl by phospho (Y251) of hCrk, Abl 1b was
overexpressed and immunoprecipitated from 293T cells. Immunoprecipitated Abl was
preincubated with phosphopeptide pY251 derived from the RT loop of SH3C of hCrk or the
corresponding unphosphorylated peptide subsequent to which an in vitro kinase assay was
performed and autophosphorylation of Abl at Y245 and Y412 was examined by western
blotting with anti-phospho (Y245) Abl and anti-phospho (Y412) Abl antibodies. As shown
in Figure 5d, preincubation with pY251 resulted in enhanced autophosphorylation of Abl 1b
at Y245 and Y412, which are indicative of Abl activation. Taken together, these results
suggest that phosphorylated Y251 in the SH3C of hCrk binds to the SH2 domain of Abl and
is likely to be directly involved in transactivation of Abl 1b by SH2 domain displacement.

Discussion
The ability of Crk to function as an adaptor protein is negatively regulated and terminated by
phosphorylation on Y221, which results in an intramolecular SH2-pTyr clamp, thereby
resulting in the disassembly of Crk-mediated signaling complexes (Feller et al., 1994; Rosen
et al., 1995; Kobashigawa et al., 2007). Here, we show that in addition to Y221, another
tyrosine residue, namely Y251, located within the highly conserved RT loop of the SH3C
domain of Crk is also concomitantly phosphorylated by the Abl and Bcr-Abl tyrosine
kinases. Our present data amend our current understanding of the role that tyrosine
Oncogene. Author manuscript; available in PMC 2012 March 23.
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phosphorylation of Crk has in signal transduction, and clearly point to more elaborate and
dynamic regulatory networks controlling the interaction between Crk and Abl.
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Prompted by observations that Y221F Crk is phosphorylated by Abl using in vitro kinase
assays, we set out to identify additional tyrosine phosphorylation sites on Crk. As the PNAY
motif in the RT loop of SH3C was essential for Crk-mediated Abl transactivation (Reichman
et al., 2005), we focused on Y251 which was a part of the PNAY sequence. In this study, we
found that Y251 is phosphorylated by Abl, in Bcr-Abl-expressing CML cells and in A431
and MDA-MB-468 cells stimulated with EGF. In addition, we show that a 16-mer
phosphopeptide flanking Y251 on Crk binds in trans to Abl SH2, and in doing so, stimulates
the kinase activity of Abl. Consistent with this interpretation, co-expression of the Y251F
Crk mutant with Abl 1b partially suppressed Abl activation, and also purified GST-hCrk
Y251F had a significantly attenuated ability to transactivate Abl compared with GST-hCrk.
In addition, GST-hCrk failed to transactivate the Abl SH2 domain mutant R171L,
suggesting that SH2 displacement by phospho (Y251) comprises one important part of the
mechanism for Abl transactivation by hCrk.
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Despite the fact that pY251 binds selectively to the Abl SH2 domain, it is noteworthy that
the sequence around phospho (Y251) in hCrk ([pY251DKT]) does not conform to the
experimentally determined consensus peptide-binding motif for the Abl SH2 domain (pY[E/
T/M][N/E/D][P/V/L]) (Birge et al., 1993; Songyang et al., 1993), In addition, Abl SH2 was
not the strongest binding partner of pY251 in the SH2 domain screen (four-fold lower
binding than the Arg SH2 in the assay), and isothermal titration calorimetry revealed a lowaffinity interaction between pY251 and Abl SH2. However, as Crk binds to Abl via the
SH3N domain (Feller et al., 1994; Ren et al., 1994), phospho (Y251) on hCrk and Abl SH2
would be expected to be present at high local concentrations in Abl–Crk complexes that may
override the apparent low affinity and drive binding of the phospho (Y251) motif to Abl
SH2. Interestingly and consistent with this notion, we observe a modest reduction in the
amount Abl that co-immunoprecipitates with hCrk Y251F compared with WT hCrk when
each is co-expressed with Abl in 293T cells (Supplementary Figure S4), suggesting that the
phospho (Y251)–Abl SH2 interaction, in addition to the Crk SH3N–Abl PXXP interaction,
contributes to the stoichiometry of binding in Abl–Crk complexes.
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Using in vitro kinase assays to reconstitute Crk and Abl in vitro, we observed that both
Y221 and Y251 were phosphorylated at the earliest time point (5 s) examined. Therefore, it
is not clear at the molecular level whether phosphorylation at Y251 (the transactivating
phosphorylation) precedes phosphorylation at Y221 (the autoinhibition phosphorylation).
Although it might be predicted that transactivation precedes inhibition, the present data
suggest that both events occur quite rapidly and are likely in dynamic equilibrium, possibly
in a manner to fine-tune Abl activation and its concomitant inhibition. Our data also imply
that a pY221/pY251 dual phosphorylated species of Crk exist in cells. This predicts an
interesting scenario in which Crk pY221/pY251 could dissociate from Abl by virtue of the
negative regulation and pY251 binds in trans to other SH2/PTB-containing proteins. Indeed,
in SH2 profiling screens, we found evidence that pY251 binds in trans to other SH2
domains selectively, which include ShcB, Brdg1 and Ship2. This interpretation would be
consistent with previous reports that pY221 Crk retains biological activity (Abassi and
Vuori, 2002), possibly by virtue of its ability to engage in new protein complexes after
dissociation from Abl. Clearly, the identification of in vivo pY251 Crk containing
complexes is an important future endeavor.
An equally important area will be the identification of additional tyrosine kinases, besides
Abl, which can phosphorylate Y251. Using bioinformatic tools such as NetPhos (ExPaSy
Proteomics Server, Swiss Institute of Bioinformatics, http://expasy.org), no kinases were
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predicted to phosphorylate Y251, although in our study, we show that both EGFR and Abl
can induce phosphorylation at Y251, at least when these kinases are overexpressed in cancer
cells. Hence, our expectation is that Abl will not be the sole kinase capable of
phosphorylating Y251 in vivo, but rather we anticipate that multiple kinases may converge
on this motif, hence integrating multiple upstream pathways with Abl. Recent evidence
suggests that Abl is activated in aggressive breast cancer cell lines (includingMDAMB-468) and possibly promotes cell invasion (Srinivasan and Plattner, 2006; Srinivasan et
al., 2008). In light of our results that reveal phosphorylation of Crk at Y251 upon EGF
stimulation of MDA-MB-468 cells and the fact that Abl is activated downstream of
activated EGFR (Plattner et al., 1999; Jones et al., 2006), phospho (Y251) on Crk may be an
important mediator of Abl activation downstream of EGFR. However, as activated EGFR
also phosphorylates Crk at the negative regulatory tyrosine Y221 (Hashimoto et al., 1998),
the relative stoichiometry of phosphorylation at Y251 and Y221 might be critical as a high
pY251/pY221 ratio on Crk typically induced by activated EGFR could favor Abl activation,
and may resolve the issue of when Abl induces a tumor-suppressing signal (Noren et al.,
2006) versus a tumor-promoting signal (Srinivasan and Plattner, 2006). In addition, it also
remains to be determined whether Y251 is phosphorylated in human cancers as Crk has
been shown to be overexpressed in several human cancers and knockdown experiments
suggest that at least one of its roles is to promote cell migration (Nishihara et al., 2002;
Miller et al., 2003; Rodrigues et al., 2005; Linghu et al., 2006; Wang et al., 2007; Fathers et
al., 2010). Notably, in Crk (−/−) mouse embryonic fibroblasts (MEFs) stably
overexpressing enhanced yellow fluorescent protein (EYFP), EYFP-hCrk or EYFP-hCrk
Y251F, WT hCrk and the Y251F mutant equally enhanced cell spreading on fibronectin, and
additionally, there was no significant difference in cell migration towards high serum in a
transwell migration assay between WT hCrk- and Y251F-expressing cells (data not shown),
suggesting that the Y251F mutant does not behave as a dominant-negative protein.
Phosphorylation of hCrk at Y251 could be a gain-of-function modification downstream of
specific stimuli such as EGF, by means of which non-canonical signaling pathways are
engaged by Crk.
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Our present observations may also have relevance to explain functional differences between
Abl activation by Crk versus CrkL. It is intriguing that the PNAY251 motif in Crk SH3C is
unique in all 266 known SH3 domains, and even diverges to a PCAY motif in CrkL. In
addition to the PNAY in the RT loop of CrkSH3C, previous studies from Pawson’s
laboratory showed that the hCrk SH2 domain contains an extended loop (called the DE
loop) that contains a PRPP motif, which binds in trans to the Abl SH3 domain (Anafi et al.,
1996). As such, double occupancy of the Abl SH2 domain with pY251 (in the RT loop of
SH3C) and that of the Abl SH3 domain (by PRPP in the DE loop of the SH2 domain) may
be required for full activation of Abl by hCrk. It is also noteworthy that such a proline-rich
insert is lacking in CrkL, suggesting another important difference between Crk and CrkL
(Figure 6), and it will be interesting to test the combined effects of pY251 and PRPP
peptides in the aforementioned kinase assays to ascertain cooperation between these motifs
in Crk.

Materials and methods
Reagents
High-performance liquid chromatography-purified biotin LC-phosphopeptides pY221
(Biotin-LC-GPEPGPpYAQPS VNTP) and pY251 (Biotin-LC-KRVPNApYDKTALALE)
were purchased from Anaspec Inc. (San Jose, CA, USA). Anti-Crk and anti-Abl were
purchased from Sigma (St Louis, MO, USA) and Calbiochem (Gibbstown, NJ, USA),
respectively. Anti-phospho (Y245) Abl, anti-phospho (Y412) Abl and anti-phospho (Y221)
Crk were purchased from Cell Signaling Technology. Anti-GST antibodies were obtained
Oncogene. Author manuscript; available in PMC 2012 March 23.
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from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Streptavidin– agarose beads
were from Pierce Scientific (Rockford, IL, USA). Glutathione–sepharose beads were
purchased from GE Healthcare (Piscataway, NJ, USA). Anti-Crk RF51 antisera have been
described previously (Reichman et al., 2005). Imatinib (trade name: Gleevec) was obtained
from Novartis. Purified Abl (beginning at the second exon-encoded sequence) was provided
by Dr Koleske, and purified Abl 1a (amino acid 47 to end) was provided by Dr Leszek
Kotula (Xiong et al., 2008; Dubielecka et al., 2010). B210 cells were obtained from George
Daley at Children’s Hospital (Boston, MA, USA). K562 cells were purchased from ATCC
(Manassas, VA, USA), whereas the KCL22, LAMA84 and MEG01 cell lines were provided
by Dr Riccardo Alessandro (University di Palermo, Italy).
Cloning and mutagenesis
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Plasmids for the expression of hCrk or cCrk have been described previously (Zvara et al.,
2001; Reichman et al., 2005). Y251 and Y221 in hCrk are numbered Y252 and Y222,
respectively, in cCrk. For clarity, we will refer to the tyrosine residue in the PNAY motif as
Y251 and the negative regulatory tyrosine as Y221 throughout this paper. pEBB plasmids
containing Crk mutant DNAs were generated using the PCR-based Quikchange mutagenesis
system (Stratagene, La Jolla, CA, USA). The following hCrk mutants were generated in this
study: Y221F, Y251F, Y221F/Y239F and Y221F/Y251F. The following chicken Crk
mutants were generated: Y221F/Q275A, Y221F/P249A and Y221F/Y251A. The cCrk
mutants W170K and Y221F have been described earlier (Escalante et al., 2000). For in vivo
studies, the murine Abl type IV or human c-Abl 1b (WT and R171L) (provided by Dr Giulio
Superti-Furga) was used (Hantschel et al., 2003).
GST-fusion proteins
GST, GST-cCrk, GST-cCrk Y221F, GST-hCrk Y251F and GST-Crk SH2 were expressed
from pGEX vectors and purified as described previously (Reichman et al., 2005). pGEX2T
encoding GST-hCrk was provided by Dr Michiyuki Matsuda (University of Kyoto, Japan)
(Matsuda et al., 1992). pGEX encoding GST-Abl SH2 was provided by Dr Leszek Kotula.
In vitro kinase assays
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In vitro kinase assays were carried out in one of the following methods. In the first method,
purified Abl 1a was incubated with a 100 molar excess of GST or GST-Crk proteins in a
kinase buffer (HNTG buffer containing 0.1% Triton X-100, 10mM MgCl2, 100mM ATP
and 5 μCi [γ32P] ATP (3000 Ci/mmol)) (Tanis et al., 2003; Reichman et al., 2005). After 30
min mixing at RT, reactions were terminated by the addition of SDS– PAGE sample buffer.
Reactions were examined by separating proteins by SDS–PAGE and exposing the gels
directly to film or to a phosphoimager plate, and by quantification using a Typhoon Storm
Phosphoimager (Amersham Biosciences Corp., Piscataway, NJ, USA). In a second method,
purified Abl 1a (amino acid 47 to end) was incubated with a 100-fold molar excess of GSThCrk in a kinase assay buffer (20mM Tris-Cl pH 7.5, 10mM MgCl2, 1mM DTT
(dithiothreitol)) in the presence of 0.1mM ATP for various times. Reactions were terminated
by addition of SDS sample buffer. In a third method, immunoprecipitated Abl 1b was
preincubated with 100 μM peptide (pY251 or Y251) or 8.75 μM GST-hCrk proteins in a
kinase assay buffer. ATP was added to 0.2mM and reactions were incubated at 25 °C for 10
or 20 min. SDS sample buffer was added to terminate each reaction.
Cell culture and DNA transfection
293T cells were maintained in Dulbecco’s modified Eagle’s medium (Cellgro, Manassas,
VA, USA) (4.5 g of glucose/l with L-glutamine) supplemented with 10% fetal calf serum.
Interleukin-3-independent Bcr-Abl or T315I Bcr-Abl expressing 32D cells (Johnson et al.,
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2009) (kindly provided by Kara Johnson and Brain Deninger, Oregon) were maintained in
RPMI 1640 containing 10% fetal calf serum. Where indicated, Bcr-Abl-expressing cells
were treated with 5μM imatinib (Novartis) for 2 h. Human CML lines K562, KCL22,
LAMA84 andMEG01 were cultured in RPMI 1640 containing 10% fetal calf serum. 293T
cells were transfected with 500 ng plasmid DNA using lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) as per the manufacturer’s protocols.
Production of phosphospecific antibodies specific for phospho (Y251) in Crk
Phospho-(Y251) Crk antibody was generated by immunizing rabbits with a synthetic 14-mer
phosphopeptide corresponding to residues surrounding Y251 of hCrk. Antibody was
purified by positive and negative peptide-affinity chromatography. All phosphospecific
antibodies were analyzed by phosphopeptide competitions using 10 μg/ml of peptides
included in the western blots.
Western blotting
Western blotting was performed after SDS–PAGE and transferred to nitrocellulose (BioRad, Hercules, CA, USA) or polyvinylidene difluoride membranes (Millipore, Billerica,
MA, USA). Densitometry was performed using the GeneTools software (Syngene,
Frederick, MD, USA).
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Immunoprecipitation
Cell lysates prepared in the HNTG buffer (20mM Hepes (pH 7.4), 150mM NaCl, 1% Triton
X-100, 10% glycerol) or the Sigma buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 1mM
EDTA, 1% Triton X-100) supplemented with 1mM sodium orthovanadate, 1mM sodium
molybdate, 1mM phenylmethylsulfonyl fluoride and aprotinin were immunoprecipitated
with anti-Abl antibodies as described previously (Hantschel et al., 2003).
SH2 domain arrays and screens
To select high-affinity SH2 domain-binding partners of pY251, the phosphopeptide was first
dissolved (10 mg/ml) in a suitable solvent (distilled water) after which it was diluted with
the rosette-loading buffer and spotted onto gelatin-coated BA79 nitrocellulose membranes.
SH2-binding assays were performed using GSH-HRP-labeled GST-SH2 probes as described
previously (Machida et al., 2007).
Streptavidin–biotin pull down assays
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GST-Abl SH2, GST or GST-Crk SH2 at 2.5 μM was incubated with pY251, Y251 or
pY221, respectively, at 25 μM in phosphate-buffered saline containing 2mM DTT for 150
min at 4 °C. In all, 20 μl streptavidin–agarose beads and 25 μg bovine serum albumin were
added to each peptide-fusion protein mix and incubated at 4 °C for 60 min. The beads were
then spun down and washed three times with the HNTG buffer containing 0.1% Triton
X-100 and 2mM DTT. Each sample was then boiled in SDS sample buffer.
Statistical analysis
The results of some experiments are the mean ± s.e.m. of three to five experiments. Oneway ANOVA (analysis of variance) with Tukey’s test was performed using GraphPad InStat
Version 3 (GraphPad, La Jolla, CA, USA) or SPSS for Windows (SPSS Inc., New York,
NY, USA).

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Crk is tyrosine phosphorylated at sites other than Y221 by the Abl kinase. (a) Equivalent
molar concentrations of GST, GST-cCrk or GST-cCrk Y221F were incubated with purified
Abl (beginning at the second exon-encoded sequence) in an in vitro kinase assay after which
reactions were analyzed by SDS–PAGE and autoradiography. (b) Immunoprecipitation of
the reaction mix in panel a was accomplished with anti-Abl antibodies, and immune
complexes were analyzed by SDS–PAGE and autoradiography. In the upper region,
phosphorylated and hyperphosphorylated Abl are indicated by asterisks. (c) Lysates of 293T
cells co-transfected with mouse Abl type IV and cCrk plasmids indicated at the top of the
blot were immunoblotted with either anti-pY (top) or anti-Crk RF51 antisera (bottom). (d)
293T cells were co-transfected with mouse Abl type IV and the respective cCrk plasmids
containing the indicated mutations in the PNAY motif, and immunoblotted as in panel c.
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Figure 2.
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Characterization of affinity-purified anti-phospho (Y251) Crk-specific antisera. (a) Lysates
of 293T cells transfected with the indicated plasmid DNAs were immunoblotted with antiphospho (Y251) Crk antisera (top panel) or anti-Crk antisera (lowermost panels). In the
second and third panels, the anti-phospho (Y251) antibody was co-incubated with 10 μg/ml
pY251 or 10 μg/ml pY221 phosphopeptides, respectively. (b) Same as panel a, but the antiphospho (Y251) antisera were co-incubated with excess GST-Crk. Anti-Crk blot is shown in
the lowest panel. (c) Lysates of 293T cells transfected with the indicated hCrk plasmids
were immunoblotted with the indicated phospho-specific antibodies (upper panels) or antiAbl and anti-Crk antibodies (lower panels). Anti-actin blot served as a loading control
(lowest panel). (d) GST-hCrk and purified Abl 1a (amino acid 47 to end) were co-incubated
at a molar ratio of 100:1 in an ATP-containing kinase buffer for up to 10 min at RT. At the
indicated times, reactions were terminated and immunoblotted with phospho-specific
antibodies as indicated. Anti-Crk blot is shown in the lowest panel. Quantification is shown
below (the ‘1 min’ time point was omitted). A full colour version of this figure is available
at the Oncogene journal online.
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Figure 3.

Crk is tyrosine phosphorylated in CML cells and after stimulation of MDA-MB-468 cells
with EGF. (a) Lysates of B210, K562, KCL22, LAMA84, MEG01 and 293T cell lines were
immunoblotted with anti-phospho (Y251), anti-phospho (Y221) or anti-Crk antisera. B210
is derived from the mouse cell line Ba/F3 by stably transfecting p210 Bcr-Abl. (b) Lysates
of WT Bcr-Abl- or T315I-Bcr-Abl-expressing 32D or K562 cells treated with imatinib (+)
or DMSO (−) were immunoblotted with anti-phospho (Y251) or anti-Crk antisera. Antiactin blot served as a loading control. (c and d) MDA-MB-468 cells were serum starved
overnight and then stimulated with EGF for 1, 5 and 30 min as in panel c or pretreated with
imatinib and stimulated with EGF for 10 min (right). Lysates were immunoblotted with antiphospho (Y251) Crk, anti-phospho (Y221) Crk, anti-phospho (Y245) Abl, antiphosphotyrosine, anti-Abl or anti-Crk antisera. Anti-actin blot served as a loading control.
(e) 293T cells were transfected with the plasmids indicated. On the right, cells were serum
starved overnight 48 h after transfection and then stimulated with EGF for 10 min. Lysates
were immunoblotted with anti-phospho (Y221) Crk, anti-phospho (Y251) Crk, antiphosphotyrosine, anti-Crk or anti-Abl antisera.
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Figure 4.

SH2 profiling to determine binding partners of the phosphopeptide pY251. (a) The design of
the rosette assay is shown, whereby biotinylated pY251 was spotted onto gelatin-coated
nitrocellulose (N1-P, N2-P and Cont-P are nonspecific phosphopeptides, whereas ‘Cont’ is
the unphosphorylated form of ‘Cont-P’). Spotting efficiency was verified using anti-pY
antisera or avidin HRP. Wells incubated with Abl, Arg ShcB SH2 and GST are shown. (b)
Summary of four independent experiments is shown. (c) Purified GST-Abl SH2, GST or
GST-cCrk SH2 proteins were incubated with biotinylated pY251 or Y251 or pY221
peptides. A pull down was subsequently achieved using streptavidin–agarose beads,
followed by analysis of the bound fraction by western blotting with anti-GST antibodies.
Representative of three experiments is shown.
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Figure 5.
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Crk activates Abl 1b through phospho (Y251). (a) Lysates of 293T cells co-transfected with
Abl 1b and the indicated hCrk mutants were immunoblotted with anti-phospho (Y245)
(upper panel), anti-Crk (middle panel) or anti-Abl antibodies (lower panel). (b) A
representative immunoblot showing the effect of Y251F substitution on Abl activation in
293T cells is shown. Quantification (±s.e. of five independent experiments) is shown. (c)
Abl 1b was overexpressed in 293T cells, immunoprecipitated and then preincubated with the
indicated proteins, followed by an in vitro kinase assay. Samples were immunoblotted with
anti-phospho (Y245) (top panel), anti-Abl (second panel), anti-p (Y251) Crk or anti-Crk
antibodies (lower panels). Representative of four independent experiments is shown with
quantification. (d) Abl 1b was overexpressed in 293T cells, immunoprecipitated and then
preincubated with pY251 or Y251 peptides, followed by an in vitro kinase assay. Samples
were immunoblotted with anti-phospho (Y412) (upper panel), anti-phospho (Y245) (middle
panel) and anti-Abl (lower panel) antibodies. Quantification of the middle panel is shown as
an average of two independent experiments.
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Figure 6.

Model for the transactivation of Abl 1b by Crk. (a) Location of Y251 in Crk based on the
NMR-derived structure (PDB ID: 2EYZ). (b) Multiple Crk/Abl interactions and the
proposed mechanism for Crk-mediated Abl transactivation is shown.
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